[Chinese consensus on definition and grading of perioperative morbidities in esophageal cancer and esophagogastric junction cancer (2023 Edition)].

Surgical treatment quality dramatically affects the overall outcome of esophagogastric cancer in China, but there is currently a lack of widely accepted definitive grading criteria for evaluating perioperative safety, making it unfeasible undertaking a surgical quality improvement project nationwide. The National Cancer Center, under the commission of the National Health Commission, has recently created the "Quality Control Indicators for Standardized Diagnosis and Treatment of Esophageal Cancer in China (2022 Version)." To ensure the successful implementation of the QC standard, aligning with it more effectively is crucial. The Expert Committee on Quality Control of Esophageal Cancer at the National Cancer Center leads work teams comprised of multidisciplinary experts, particularly those in thoracic surgery, to establish a consensus on the definition and grade for perioperative morbidity. This expert consensus is developed by applying the international standardized guideline development methodology based on the latest research evidence and China's national conditions. This consensus covers the framework of 8 major categories, precisely 45 of the most common perioperative morbidities of esophagogastric cancer. This consensus aims to establish a standardization of surgical management for esophagogastric cancer in China, ultimately improving its effectiveness nationwide.外科治疗质量关乎食管癌及食管胃交界部癌的总体疗效，然而在评价围手术期安全性方面国内尚缺乏被广泛接受的定义分级标准，导致难以开展国家层面的外科质量改进工作。近期，由国家卫生健康委员会委托国家癌症中心制订了《中国食管癌规范诊疗质量控制指标（2022版）》。为了更好地配合该质控标准顺利实施，由国家癌症中心食管癌质控专家委员会牵头组织以胸外科为主的多学科专家和工作团队，应用国际规范的指南制订方法，基于最新研究证据和我国国情，制订了本项专家共识。本共识共涵盖8大类并发症项目的框架，包括45项最常见的食管癌围手术期并发症。本共识以期为我国食管癌外科诊疗工作的规范开展提供参考，进而提升我国食管癌总体疗效。.